

Bimekizumab effect on health-related quality of life and symptoms over 3 years: Data from BE HEARD EXT

Jacek C. Szepietowski,^{1–3} Raj Chovatiya,^{4,5} Sylke Schneider-Burrus,⁶ Pablo Fernandez-Peñas,⁷ Ali Shahbaz,⁸ Hideki Fujita,⁹ Jérémy Lambert,¹⁰ Evelina van Ree,¹¹ Bengt Hoepken,¹² Nicola Tilt,¹³ Vivian Y. Shi¹⁴

P1344

¹Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wrocław University of Science and Technology, Wrocław, Poland; ²Cityclinic: Medical and Psychological Center, Wrocław, Poland; ³European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany; ⁴Rosalind Franklin University of Medicine and Science Chicago Medical School, North Chicago, Illinois, USA; ⁵Center for Medical Dermatology + Immunology Research, Chicago, Illinois, USA; ⁶Center for Skin Surgery, Havelklinik, Berlin, Germany; ⁷Department of Dermatology, Westmead Hospital, University of Sydney, Westmead, New South Wales, Australia; ⁸Texas A&M School of Medicine, Austin, Texas, USA; ⁹Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan; ¹⁰UCB, Courbevoie, France; ¹¹UCB, Breda, The Netherlands; ¹²UCB, Monheim am Rhein, Germany; ¹³UCB, Slough, UK; ¹⁴Department of Dermatology, University of Washington, Seattle, Washington, USA

Objective

To report the impact of bimekizumab (BKZ) on patient-reported health-related quality of life (HRQoL) and hidradenitis suppurativa (HS) symptoms in patients with moderate to severe HS through 3 years of treatment.

Introduction

- HS is a chronic, progressive, inflammatory skin disease with a substantial and cumulative burden on HRQoL.^{1–3}
- Core HS symptoms include skin pain, itch, smell or odour and drainage.^{1–3} These symptoms impact HRQoL, including physical, psychological, social, sexual and occupational functioning throughout a patient's life course.^{1–3}
- BKZ is a humanised IgG1 monoclonal antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A.⁴

Methods

- Data were pooled from the phase 3 BE HEARD I&II trials (NCT04242446, NCT04242498) and their open-label extension, BE HEARD EXT (NCT04901195), for patients with moderate to severe HS.^{5,6}
- Data are reported for patients randomised to BKZ 320 mg from baseline in BE HEARD I&II who entered BE HEARD EXT (BKZ Total).
- HRQoL outcomes are reported to Year 3 (Week 148):
 - Dermatology Life Quality Index (DLQI)** total score and the proportions of patients achieving DLQI scores of 0/1 (no effect) and 0–5 (no/small effect; **Figure 1A**).
 - HS Quality of Life (HiSQoL)** proportions of patients achieving a total score ≤4 (no impact) and ≤14 (no/mild impact) and HiSQoL total score change from baseline (**Figure 1B**).
- HS symptoms are reported to Year 3:
 - HS Symptom Questionnaire (HSSQ)** mean item scores for skin pain, itch, smell or odour and drainage or oozing (scored 0–10 on numeric rating scales; **Figure 1C**).
- Data are reported as observed case (OC).

Results

- Of the 1,014 patients in the BE HEARD I&II trials, 868 were randomised to BKZ at baseline.
 - Of those, 556 patients completed Year 1 (Week 48) and entered BE HEARD EXT; 447 and 367 patients remained at Year 2 (Week 96) and Year 3 (Week 148), respectively.

Impact of BKZ on HRQoL

- From baseline to Year 1, the mean DLQI total score decreased from 11.0 (very large effect) to 5.0 (small effect). This reduction was maintained to Year 3 (**Figure 1A** and **Figure 2**).
 - The proportion of patients achieving DLQI 0/1 numerically improved from Year 1 to Year 3 (**Table 1**).
 - The proportion of patients achieving DLQI 0–5 at Year 1 was maintained through Year 3 (**Table 1**).
- The mean improvement from baseline in HiSQoL total score observed at Year 1 was maintained to Year 3 (**Figure 1B** and **Table 1**).
 - The proportion of patients reporting no impact of HS on their HRQoL (HiSQoL total score ≤4) increased from baseline to Year 1 and was maintained through Year 3 (**Table 1**).
 - Similarly, the proportion of patients reporting no/mild impact of HS on their HRQoL (HiSQoL total score ≤14) at baseline increased to Year 1 and was maintained through Year 3 (**Figure 3**).

Impact of BKZ on HS symptoms

- Baseline HSSQ skin pain, itch, smell or odour and drainage or oozing mean scores were 5.8, 4.9, 4.6 and 5.1, respectively, indicative of moderate to severe symptoms (**Figure 1C** and **Figure 4**).
- Improvements were observed at Year 1 and Year 3, with mean scores decreasing to 2.8, 2.9, 2.6 and 2.7 at Year 1 and 2.0, 2.4, 2.1 and 2.1 at Year 3 for skin pain, itch, smell or odour and drainage or oozing, respectively, indicating milder symptom severity (**Figure 1C** and **Figure 4**).

Conclusions

Patients treated with bimekizumab achieved improvements in HRQoL at Year 1, as assessed by DLQI and HiSQoL, which were maintained through Year 3. Improvements in HS skin pain, itch, smell or odour and drainage or oozing symptoms were also observed at Year 1 and maintained through Year 3, demonstrating disease control and reduced cumulative disease burden with bimekizumab treatment.

Summary

The impact of BKZ treatment on HRQoL and HS symptoms was assessed in patients with moderate to severe HS. BKZ treatment resulted in meaningful improvements in HRQoL and HS symptoms by Year 1, which were maintained through Year 3.




Figure 1 Patient-reported HRQoL and symptom measures




Figure 2 Mean DLQI total score over 3 years




Figure 3 Proportion of patients achieving HiSQoL total score ≤14 over 3 years





Figure 4 HSSQ mean scores by item over 3 years

Table 1 HRQoL outcomes over 3 years

	Baseline N=868	Year 1 N=556	Year 2 N=447	Year 3 N=367
DLQI (score range: 0–30)				
DLQI 0/1, % (n/N)	4.7 (26/551)	27.4 (151/551)	33.9 (151/445)	38.1 (137/360)
DLQI 0–5, % (n/N)	24.7 (136/551)	68.2 (376/551)	68.1 (303/445)	71.7 (258/360)
HiSQoL (total score range: 0–68)				
HiSQoL total score CFB, mean (SD) n	N/A	–13.9 (12.1) 551	–14.4 (13.2) 442	–15.2 (14.1) 358
HiSQoL total score ≤4, % (n/N)	18.0 (99/551)	64.5 (358/555)	71.5 (318/445)	72.8 (262/360)

References: ¹Kaur AP et al. Skin Health Dis 2023;3:e214. ²Montero-Vilchez T et al. Int J Environ Res Public Health 2021;18:6709. ³Doroudian Tehrani M et al. J Eur Acad Dermatol Venereol 2025;39:1395–409. ⁴Adams R et al. Front Immunol 2020;11:1894. ⁵Kimball AB et al. Lancet 2024;403:2504–19. ⁶BE HEARD EXT: Sayed CJ et al. J Am Acad Dermatol 2026;94:867–78. **Author Contributions:** Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: **JCS, RC, SSB, PFP, AS, HF, JL, EVR, BH, NT, VYS.** Drafting of the publication, or reviewing it critically for important intellectual content: **JCS, RC, SSB, PFP, AS, HF, JL, EVR, BH, NT, VYS.** Final approval of the publication: **JCS, RC, SSB, PFP, AS, HF, JL, EVR, BH, NT, VYS.** **Author Disclosures:** These studies were funded by UCB. Medical writing support was provided by Costello Medical and funded by UCB. **JCS:** Consultant and advisory board member of AbbVie, Almirall, Boehringer Ingelheim, Galderma, LEO Pharma, Novartis, Pierre Fabre, Sanofi, Genzyme and UCB; speaker for AbbVie, Almirall, Boehringer Ingelheim, Eli Lilly and Company, Janssen, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi Genzyme and UCB; investigator for AbbVie, Acelyrin, Almirall, Hermal, Amgen, AnaptysBio, Argenc, Asian, Boehringer Ingelheim, Biocom, Bio Thera, Bristol Myers Squibb, Celltrion, CurateQ Biologics, DICE Therapeutics, Eli Lilly and Company, Galapagos, Galderma, Helix AG, Incyte, InflaRx, Janssen, Kiniksa, Kymab Limited, LEO Pharma, MedImmune, Menlo Therapeutics, Merck, MoonLake Immunotherapeutics, Novartis, Pierre Fabre, Pfizer, Regeneron Pharmaceuticals, Takeda, Teva, Trevi Therapeutics, UCB, Uni Therapeutics and Ventyx Bioscience. **RC:** Served as an advisor, consultant, speaker, and/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, Argenc, Astria Therapeutics, Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, Cln Skin Care, Dermavant, DKSH, Eli Lilly and Company, EMD Serono, EPI Health, Formation Bio, Forte Biosciences, Galderma, Genentech, GSK, Incyte, Imagen Bio Inc., Indero, Johnson & Johnson, Kenvue, LEO Pharma, L'Oréal, Nektar Therapeutics, Nia Health, Novan, Novartis, Opzdivo, Organon, Pfizer, RAPT, Regeneron, Sanofi, Sitrax, SUN Pharma, Takeda, TReX Bio, UCB, Zai Lab, ZenZema and Zuellig Pharma. **SSB:** Received honoraria for participation in advisory boards, in clinical trials, and/or as a speaker for AbbVie, Biogen, Boehringer Ingelheim, Hexal, MoonLake Immunotherapeutics, Novartis, Sanofi and UCB. **PFP:** Served on advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, L'Oréal, LEO Pharma, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, UCB and Zuellig Pharma; received research funding from Pfizer; conducted clinical trials for AbbVie, Akesbio, Alumis, Amgen, Apogee, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, CellDex, CSL, Chugai, Eisai, Eli Lilly and Company, Galderma, Incyte, Johnson & Johnson, Jiangsu Hengrui, KoBioLabs, Merck, Merck Sharp & Dohme, miRagen, Moderna, OncoSec, Pfizer, Regeneron, Sanofi and UCB. **AS:** No relevant conflicts of interest. **HF:** Received research grant or honoraria for speaker and/or consultancy from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly and Company, Fuji Pharma, Janssen, Kaken, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, MSD, Novartis, Pfizer, Sanofi, Sato Pharma, Sun Pharma, Taiho, Takeda, Torii, UCB and Ushio. **JL, EVR, BH, NT:** Employees and shareholders of UCB. **VYS:** On the board of directors for the Hidradenitis Suppurativa Foundation (HSF); advisor for the National Eczema Association; stock shareholder of Learn Health; served as an advisory board member, investigator, speaker and/or received research funding from AbbVie, Almirall, Altus Labs/Quell, Alumis, Apogee, Arcutis, Arista Therapeutics, Bain Capital, Boehringer Ingelheim, Burt's Bees, Castle Bioscience, Ceraclear, Dermavant, Dermira, Eli Lilly and Company, Galderma, Genentech, GpSkin, Incyte, Insmed, Kiniksa, LEO Pharma, Menlo Therapeutics, MoonLake Immunotherapeutics, MYOR, Navigator Medicine, Novartis, Onuka, Pfizer, Polyfins Technology, Regeneron, Sanofi Genzyme, Skin Actives Scientific, SUN Pharma, Takeda, Target-PharmaSolutions, UCB and ZuraBio. **Acknowledgements:** These studies were funded by UCB. We thank the patients and their caregivers in addition to the investigators and their teams who contributed to this study. The authors also thank Susana Lobo Berastegui, MSc, of UCB, for editorial review during poster development and publication coordination, Sarah Rose Slate, MPH, Costello Medical, USA for medical writing and editorial assistance and the Costello Medical Creative team for design support. All costs associated with development of this poster were funded by UCB.



To receive a copy of this poster and the study design figure, scan the QR code. Link expiration: 1 January 2027